PALOMARecruiting

PALOMA

Gender
Women and men
Age
18–75 years
Trial type
Interventional
Line of therapy
First line
Phase
Phase II

What is this trial about?

The PALOMA study is investigating the efficacy of a novel combination chemotherapy agent (CPX-351) compared with conventional therapy for high-risk myelodysplastic syndrome prior to allogeneic stem cell transplantation.

Detailed description

Allogeneic stem cell transplantation is currently the only curative option prior to allogeneic stem cell transplantation. To bridge the gap until allogeneic stem cell transplantation, conventional chemotherapy or milder forms of chemotherapy are traditionally used. Despite these therapies, stem cell transplantation cannot be performed in all patients. CPX-351 is a new combination chemotherapy regimen that has already demonstrated good results in acute leukemias. The study is now investigating whether CPX-351 leads to higher and more durable response rates, including a more favorable safety profile and long-term outcomes, compared to the conventional treatment approaches currently used prior to stem cell transplantation.

Trial sites

26 trial sites in Germany are listed. Find a site near you.

  • Universitätsklinikum Aachen AöR

    Pauwelsstrasse 30, 52074 Aachen

    Status unknown

  • Universitätsklinikum Augsburg

    Stenglinstrasse 2, 86156 Augsburg

    Active, not recruiting

  • Charité – Universitätsmedizin Berlin

    Berlin

    Status unknown

  • Helios Klinikum Berlin-Buch GmbH

    Schwanebecker Chaussee 50, 13125 Berlin

    Status unknown

  • Universitätsklinikum Bonn

    Venusberg-Campus 1, 53127 Bonn

    Active, not recruiting

  • Klinikum Chemnitz gGmbH

    Chemnitz

    Status unknown

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time.

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry (NCT04061239) and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.